Risperidone Versus Quetiapine: Risk of Developing Metabolic Syndromes in Patients Suffering from Psychiatry Disorders of a Health Care Center

Asian Journal of Pharmaceutical and Health Sciences,2020,10,3,2309-2317.
Type:Original Article
Author(s) affiliations:

R. Venkata Ramudu1, Shaik Kareemulla*2, K. Chaitanya Bharathi3, P. Tejaswini3, Shaik Yaseen Vamaliya3, Shaik Yasmeen3

1Assistant professor, Department of Psychiatry, Government general hospital – RIMS, Kadapa, Andra Pradesh, INDIA.

2Assistant professor, Department of Pharmacy practice, P. Rami reddy memorial college of pharmacy, Kadapa, Andra Pradesh, INDIA.

3Pharm D Intern, Department of Pharmacy practice, P. Rami reddy memorial college of pharmacy, Kadapa, Andra Pradesh, INDIA.


Second generation atypical antipsychotics (SGAAPs) have been used as first-line drugs in psychiatric practice for a wide range of psychotic disorders. These drugs effectively exert therapeutic effects of positive symptoms, negative symptoms, and cognitive impairments. Utilization of SGAAPs in this present scenario has raised questions with respect to their tolerability and adverse drug reactions such as obesity, cardiovascular disorders and other metabolic disorders. The aim of our research project is to compare the risk of metabolic disorders associated with the usage of drugs (Risperidone versus Quetiapine) in psychiatric patients. Our study objective is to assess prognosis reports, compare BMI, FBS, lipid profile and counsel psychiatric patients by providing patient information leaflets. This is a hospital based prospective observational randomized control trial was conducted for a period of 6 months at Government General Hospital (RIMS), Kadapa. 50 patients (25 patients prescribed with Risperidone & 25 patients prescribed with Quetiapine) were recruited based on study criteria.In a total of 50 patients, it was found that 15 patients were males and 35 patients were females. Maximum number of patients (i.e., 17 patients) belonged to 36-50 years’ age group. Majority of patients (i.e., 20 patients) receiving SGAAPs had clinical diagnosis as schizophrenia. During 180 to 200 days of study, 3 follow ups were done, with time duration of 30 days between each follow up. The mean value of BMI was 23.46 for Risperidone patients & 22.01 for Quetiapine patients. The mean value of FBS was 90.52 for Risperidone patients & 89.40 for Quetiapine patients. The mean value of total cholesterol was 157.04 for Risperidone patients & 150.32 for Quetiapine patients. The mean value of triglycerides was 123.72 for Risperidone patients & 118.76 for Quetiapine patients. On assessing the above results, we have concluded that Risperidone has increased risk of developing metabolic syndromes when compared to Quetiapine.

Fig. 2: Patients suffering from metabolic disorders